Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ZYMEWORKS INC.

(ZYME)
  Report
Delayed Nyse  -  01:00 2022-11-25 pm EST
7.840 USD   -2.49%
11/22Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium
AQ
11/22Zymeworks Announces Participation in Upcoming Investor Conference
BU
11/21HC Wainwright Adjusts Price Target on Zymeworks to $10 From $8, Maintains Neutral Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SVB Securities Adjusts Zymeworks' Price Target to $19 from $18, Keeps Outperform Rating

05/27/2022 | 10:47am EST


ę MT Newswires 2022
All news about ZYMEWORKS INC.
11/22Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Recepto..
AQ
11/22Zymeworks Announces Participation in Upcoming Investor Conference
BU
11/21HC Wainwright Adjusts Price Target on Zymeworks to $10 From $8, Maintains Neutral Ratin..
MT
11/21Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Recepto..
BU
11/08Transcript : Zymeworks Inc., Q3 2022 Earnings Call, Nov 08, 2022
CI
11/08Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results
BU
11/08Earnings Flash (ZYME) ZYMEWORKS Posts Q3 Loss $-0.66
MT
11/08Zymeworks Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sep..
CI
11/02North American Morning Briefing: Caution to -2-
DJ
11/01HC Wainwright Downgrades Zymeworks to Neutral From Buy, Lowers Price Target to $8 From ..
MT
More news
Analyst Recommendations on ZYMEWORKS INC.
More recommendations
Financials (USD)
Sales 2022 195 M - -
Net income 2022 -50,4 M - -
Net cash 2022 206 M - -
P/E ratio 2022 -6,32x
Yield 2022 -
Capitalization 505 M 505 M -
EV / Sales 2022 1,54x
EV / Sales 2023 3,75x
Nbr of Employees 286
Free-Float 86,5%
Chart ZYMEWORKS INC.
Duration : Period :
Zymeworks Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZYMEWORKS INC.
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 7,84 $
Average target price 12,31 $
Spread / Average Target 57,0%
EPS Revisions
Managers and Directors
Kenneth Harry Galbraith Chairman & Chief Executive Officer
Neil A. Klompas Chief Financial Officer
Christopher Astle Chief Financial Officer & Senior Vice President
Neil Josephson Vice President-Clinical Development
Paul A. Moore Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ZYMEWORKS INC.-52.17%505
VERTEX PHARMACEUTICALS42.52%80 339
REGENERON PHARMACEUTICALS, INC.16.44%78 631
BIONTECH SE-39.93%37 632
WUXI APPTEC CO., LTD.-30.90%33 214
GENMAB A/S20.53%28 930